Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 6:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 241 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Severe Acute Respiratory Infection Clear all
Completed Phase 2 Interventional Results available

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

NCT04402957
View directory record Official record
Conditions
COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury, Acute Respiratory Distress Syndrome
Interventions
LSALT peptide, Placebo
Drug
Lead sponsor
Arch Biopartners Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
San Diego, California • Fort Lauderdale, Florida • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Jul 24, 2026, 6:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections

NCT04623138
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Not listed
Lead sponsor
Evidation Health
Industry
Eligibility
18 Years and older
Enrollment
847 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Jul 24, 2026, 6:05 AM EDT
Completed Phase 2 Interventional Results available

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04551898
View directory record Official record
Conditions
Covid19
Interventions
BGB-DXP593, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
DeLand, Florida • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Jul 24, 2026, 6:05 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450
View directory record Official record
Conditions
Viral Lung Infection and Acute Respiratory Failure
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
72
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 24, 2026, 6:05 AM EDT
Completed No phase listed Observational

Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)

NCT05074719
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19, Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
10 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jul 24, 2026, 6:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants

NCT05129475
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07321332/ritonavir, Ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Jul 24, 2026, 6:05 AM EDT
Completed No phase listed Observational

Northern Colorado COVID-19 Biobank

NCT04603677
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Fort Collins, Colorado • Greeley, Colorado • Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Jul 24, 2026, 6:05 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

NCT04421508
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infection
Interventions
INOpulse, Placebo
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Phoenix, Arizona • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jul 24, 2026, 6:05 AM EDT
Terminated Phase 2 Interventional Results available

COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes

NCT04537299
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jul 24, 2026, 6:05 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

NCT04642638
View directory record Official record
Conditions
Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease
Interventions
INO-4800, CELLECTRA® 2000, Placebo
Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,307 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
16
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Jul 24, 2026, 6:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

NCT04661839
View directory record Official record
Conditions
COVID-19
Interventions
COVID-HIGIV, Placebo (saline)
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Jul 24, 2026, 6:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation

NCT04357782
View directory record Official record
Conditions
COVID-19, Hypoxia
Interventions
L-ascorbic acid
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Jul 24, 2026, 6:05 AM EDT
Completed Phase 3 Interventional Results available

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

NCT04510194
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Metformin, Placebo, Fluvoxamine, Ivermectin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 85 Years
Enrollment
1,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Sylmar, California • Aurora, Colorado • Golden, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 24, 2026, 6:05 AM EDT
Completed Phase 2 Interventional Results available

Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)

NCT04448756
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
M5049, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Jul 24, 2026, 6:05 AM EDT
Withdrawn Phase 1 Interventional

Intermediate IND Severe Illness COVID-19 CP

NCT04411602
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome, COVID
Interventions
SARS-CoV-2 plasma
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Novi, Michigan • Southfield, Michigan • Warren, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 24, 2026, 6:05 AM EDT
No Longer Available No phase listed Expanded access

Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients

NCT04420988
View directory record Official record
Conditions
COVID-19, SARS-CoV 2, SARS-CoV Infection
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Jul 24, 2026, 6:05 AM EDT
Completed Not applicable Interventional Results available

CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))

NCT04756141
View directory record Official record
Conditions
Diabetes Mellitus, Covid19
Interventions
Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Jul 24, 2026, 6:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

NCT05263895
View directory record Official record
Conditions
Bioavailability
Interventions
PF-07321332/ritonavir, PF-07321332
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Jul 24, 2026, 6:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness

NCT05175690
View directory record Official record
Conditions
COVID19
Interventions
Diagnostic Software as Medical Device
Diagnostic Test
Lead sponsor
AudibleHealth AI, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jul 24, 2026, 6:05 AM EDT
Withdrawn No phase listed Observational

Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)

NCT00073086
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 24, 2026, 6:05 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

NCT04992273
View directory record Official record
Conditions
COVID-19
Interventions
casirivimab+imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Minute to 12 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Anaheim, California • Miami, Florida • Stony Brook, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 24, 2026, 6:05 AM EDT
Terminated Phase 2 Interventional Results available

Tocilizumab for Patients With Cancer and COVID-19 Disease

NCT04370834
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis, Severe Acute Respiratory Distress Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Tocilizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Rockville, Maryland • Las Vegas, Nevada • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 24, 2026, 6:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

NCT04426695
View directory record Official record
Conditions
COVID-19
Interventions
REGN10933+REGN10987 combination therapy, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
96
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Jul 24, 2026, 6:05 AM EDT